Nature medicine
Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial.
Timothy A Yap, Randy F Sweis, Ulka Vaishampayan, Deepak Kilari, Justin F Gainor, Meredith McKean, Minal Barve, Ahmad A Tarhini, Bruno Bockorny, Guru Sonpavde, David Park, Sunil Babu, Yawen Ju, Lan Liu, Susan Henry
Published: 202610.1038/s41591-025-04157-w
Abstract
Although immune checkpoint inhibitor therapies have revolutionized oncology, many cancers are unresponsive or develop resistance that involves transforming growth factor-β1 (TGFβ1). This multicenter, open-label, phase 1 study (DRAGON trial, SRK-181-0…
Preview only. Read the full abstract at the source